Curio Digital Therapy for the Treatment of Post-partum Depression (SuMMER)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05958095 |
Recruitment Status :
Active, not recruiting
First Posted : July 24, 2023
Last Update Posted : July 24, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
PostPartum Depression | Device: MamaLift Plus Device: Digital Sham App | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 142 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | The data of 200 participants will be collected and analyzed for this study. Participants will be selected from a pool of patients who have given birth in the last three months prior to the study start date and been diagnosed with postpartum depression or have experienced depressive symptoms. The study aims to recruit a diverse study cohort across age, race, and SES to reflect the intended user population in the United States. |
Masking: | Single (Participant) |
Masking Description: | Participants are not aware of whether they are receiving the MamaLift Plus interventional device or the digital placebo device. The applications have the same user interface and require a similar amount of time to complete activities. Participants in both arms will receive treatment as usual in addition. |
Primary Purpose: | Treatment |
Official Title: | Supporting Maternal Mental Health and Emotional Regulation (SuMMER): Assessment of the Clinical Effectiveness of a Mobile Application for Patients With Postpartum Depression |
Actual Study Start Date : | April 1, 2023 |
Actual Primary Completion Date : | May 24, 2023 |
Estimated Study Completion Date : | August 15, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: MamaLift Plus
Principles of Cognitive Behavioral Therapy used to treat PPD with App
|
Device: MamaLift Plus
MamaLift Plus is a digital therapeutic designed to augment usual care and support the treatment of mild-to-moderate postpartum depression (PPD). This mobile-based intervention is grounded on principles of Cognitive Behavioral Therapy (CBT) and Interpersonal Therapy (IPT) and includes key content areas for the treatment management of PPD. It also includes recent developments in acceptance and commitment-based therapies, specifically for the perinatal context. |
Sham Comparator: Digital Sham App
Content on general mental health and wellbeing topics delivered with sham App
|
Device: Digital Sham App
The digital sham app delivers content, tips, and suggestion for general wellbeing support. |
- EPDS Score [ Time Frame: 9 week period ]Proportion of women that improve EPDS by >= 4 points at their end of study assessment.
- EPDS Score improvement [ Time Frame: 9 week period ]Proportion of women that improve EPDS to < 13 points at their end of study assessment
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
Sexes Eligible for Study: | Female |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | Adult females who delivered live births in the 3 months prior to study start |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Participants must be able to read, write and speak English; 3. Participants must provide written informed consent prior to enrollment; 4. Participants must be 18 to 50 years of age at the time of enrollment; 5. Participants must have had a live childbirth <=3 months prior to their enrollment into the study; 6. Participants who have a score of greater than or equal to 13 but not exceeding 19 on the Edinburgh Postnatal Depression Scale (EPDS) during initial screening visit/call; 7. Depression diagnosis needs to be confirmed by licensed behavioral health therapist or medical professional; 8. Participants must answer "0/Never" or "1/Hardly Ever" to the self-harm question on EPDS (Question #10); 9. Participants must be willing to use a mobile app and own an iOS or android enabled mobile phone or device; 10. Participants must have wireless internet connectivity in their home (or have access to internet connectivity) and be willing to connect devices via a Wi-Fi network
Exclusion Criteria:
-
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05958095
United States, New York | |
Healthcare Innovation and Technology Lab | |
New York, New York, United States, 10032 |
Principal Investigator: | Stan Kachnowski, PhD | Healthcare Innovation Technology Lab |
Responsible Party: | Stan Kachnowski, Chair, Healthcare Innovation Technology Lab |
ClinicalTrials.gov Identifier: | NCT05958095 |
Other Study ID Numbers: |
CU-T-003 |
First Posted: | July 24, 2023 Key Record Dates |
Last Update Posted: | July 24, 2023 |
Last Verified: | July 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
PostPartum depression (PPD), symptoms of PPD, Anxiety, Peri-natal depression, mild-to-moderate depression |
Depression, Postpartum Depression Depressive Disorder Behavioral Symptoms Mood Disorders |
Mental Disorders Puerperal Disorders Pregnancy Complications Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases |